Severity
Low
FDA Drug recall · Reported November 1, 2017
Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.
AbbVie Inc. recalled AndroGel (testosterone gel) 1.62%, 40.5mg in 2.5g aluminum foil packet, 30 Packets per ca… - a low-severity action.
AndroGel (testosterone gel) 1.62%, 40.5mg in 2.5g aluminum foil packet, 30 Packets per ca… was recalled by AbbVie Inc. in November 1, 2017. Reason: Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.. Check the official notice for the remedy. Verify recall #D-0034-2018 with the FDA Drug before acting.
The recall
AbbVie Inc. issued this low-severity FDA Drug recall-Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions..
Sourced from official FDA Drug enforcement records. Verify recall #D-0034-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0034-2018) was formally reported on November 1, 2017, with the manufacturer initiating the action on September 8, 2017. It is classified under Low severity (Class III), with a current status of Terminated. AbbVie Inc. is listed as the recalling firm, operating out of North Chicago, IL. Federal records list the affected scope as 48 cartons (30 foil packets per carton).
The documented reason for this recall is: Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions. Distribution data in the federal record shows the product reached: AZ. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug and 1 from AbbVie Inc. - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
48 cartons (30 foil packets per carton)
Related Recalls
6
5 from same agency
AndroGel (testosterone gel) 1.62%, 40.5mg in 2.5g aluminum foil packet, 30 Packets per carton. Rx Only. Marketed by: AbbVie Inc., North Chicago, IL 60064 USA. NDC: 0051-8462-30
Temperature Abuse: Prolonged exposure to temperatures outside of labeled storage conditions.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0034-2018 |
| Date reported | November 1, 2017 |
| Date initiated | September 8, 2017 |
| Recalling firm | AbbVie Inc. |
| Firm location | North Chicago, IL |
| Affected scope | 48 cartons (30 foil packets per carton) |
| Distribution | AZ |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 1, 2017. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.